These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 7259691)

  • 21. Evaluation of a new antinauseant drug for the prevention of motion sickness.
    Graybiel A; Knepton J
    Aviat Space Environ Med; 1977 Sep; 48(9):867-71. PubMed ID: 334151
    [No Abstract]   [Full Text] [Related]  

  • 22. Histaminergic response to Coriolis stimulation: implication for transdermal scopolamine therapy of motion sickness.
    Wang ET; Zhou DR; He LH
    Aviat Space Environ Med; 1992 Jul; 63(7):579-82. PubMed ID: 1616432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of antimotion sickness drug side effects on performance.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood MJ; Mims ME
    Aviat Space Environ Med; 1985 Apr; 56(4):310-6. PubMed ID: 3888169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transdermal scopolamine, oral meclizine, and placebo in motion sickness.
    Dahl E; Offer-Ohlsen D; Lillevold PE; Sandvik L
    Clin Pharmacol Ther; 1984 Jul; 36(1):116-20. PubMed ID: 6734040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Side effects of antimotion sickness drugs.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood M; Vekovius WA
    Aviat Space Environ Med; 1984 Feb; 55(2):113-6. PubMed ID: 6696702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of a randomized double-blind crossover trial of scopolamine versus placebo administered by transdermal patch for the control of cisplatin-induced emesis.
    Longo DL; Wesley M; Howser D; Hubbard SM; Anderson T; Young RC
    Cancer Treat Rep; 1982 Nov; 66(11):1975-6. PubMed ID: 6890407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transdermal scopolamine in the prevention of motion sickness at sea.
    Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G
    Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transderm scopolamine efficacy related to time of application prior to the onset of motion.
    Levy GD; Rapaport MH
    Aviat Space Environ Med; 1985 Jun; 56(6):591-3. PubMed ID: 4015572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of antimotion sickness drugs on habituation to motion.
    Wood CD; Manno JE; Manno BR; Odenheimer RC; Bairnsfather LE
    Aviat Space Environ Med; 1986 Jun; 57(6):539-42. PubMed ID: 3718377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermal scopolamine for motion sickness.
    Med Lett Drugs Ther; 1981 Oct; 23(21):89-90. PubMed ID: 7027000
    [No Abstract]   [Full Text] [Related]  

  • 31. Differential effects of scopolamine and amphetamine on microcomputer-based performance tests.
    Kennedy RS; Odenheimer RC; Baltzley DR; Dunlap WP; Wood CD
    Aviat Space Environ Med; 1990 Jul; 61(7):615-21. PubMed ID: 2386447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacologic agents for preventing and treating motion sickness].
    Shashkov VS; Sabaev VV
    Kosm Biol Aviakosm Med; 1981; 15(1):9-18. PubMed ID: 6111621
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of phenytoin in the prevention of motion sickness.
    Chelen W; Kabrisky M; Hatsell C; Morales R; Fix E; Scott M
    Aviat Space Environ Med; 1990 Nov; 61(11):1022-5. PubMed ID: 2256875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal Scopolamine for Motion Sickness.
    Stankovic AS; Alvarenga DL; Coleman Daniels VR; Simmons RG; Buckey JC; Putcha L
    Aerosp Med Hum Perform; 2019 Nov; 90(11):917-924. PubMed ID: 31666152
    [No Abstract]   [Full Text] [Related]  

  • 35. A comparison of effectiveness of some antimotion sickness drugs using recommended and larger than recommended doses as tested in the slow rotation room. NSAM-945.
    Wood CD; Graybiel A; Kennedy RS
    Res Rep U S Nav Sch Aviat Med; 1965 Jul; ():1-9. PubMed ID: 5322559
    [No Abstract]   [Full Text] [Related]  

  • 36. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
    Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y
    Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of transcutaneous scopolamine and depth on diver performance.
    Williams TH; Wilkinson AR; Davis FM; Frampton CM
    Undersea Biomed Res; 1988 Mar; 15(2):89-98. PubMed ID: 3363755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention and treatment of space sickness in shuttle-orbiter missions.
    Graybiel A
    Aviat Space Environ Med; 1979 Feb; 50(2):171-6. PubMed ID: 36067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of transdermal scopolamine on simulated ship navigation and attention/reaction time.
    Howland J; Rohsenow DJ; Minsky S; Snoberg J; Tagerud S; Hunt SK; Almeida A; Greece J; Allensworth-Davies D
    Int J Occup Environ Health; 2008; 14(4):250-6. PubMed ID: 19043911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.